Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Genetics

TERT mutation in urogenital cancers

Nature Reviews Urology volume 11, page 3 (2014)Cite this article

Subjects

Following on from the observation that ∼70% of bladder tumours harbour somatic mutations in the TERT gene promoter, researchers have expanded this analysis to include other urogenital cancers. Data confirmed the high rate of mutations in urothelial carcinoma and revealed low rates in kidney tumours; no mutations were detected in prostate or testicular cancers. In addition, TERT mutation was associated with increased invasiveness in bladder cancer cell culture and invasive disease in patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wu, S. et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur. Urol. 10.1016/j.eururo.2013.10.038

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

TERT mutation in urogenital cancers. Nat Rev Urol 11, 3 (2014). https://doi.org/10.1038/nrurol.2013.279

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2013.279

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing